Adam C. Bledsoe

Adam C. Bledsoe

Auto-generated profile, based on publicly available information

Adam C. Bledsoe

Division of Gastroenterology and Hepatology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
EDEvan S. Dellon
Evan S. Dellon
KPKathryn A. Peterson
Kathryn A. Peterson
JMJoseph A. Murray
Joseph A. Murray
GFGary W. Falk
Gary W. Falk
NGNirmala Gonsalves
Nirmala Gonsalves
IHIkuo Hirano
Ikuo Hirano
Eosinophilic gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. Mast-cell activity may contribute to the pathogenesis of the conditions. AK002 (lirentelimab) is an anti–Siglec-8 antibody that depletes eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis.

1 July 2019 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
ABAdam C. Bledsoe
Adam C. Bledsoe
KKKatherine S. King
Katherine S. King
JLJoseph J. Larson
Joseph J. Larson
MSMelissa Snyder
Melissa Snyder
IAImad Absah
Imad Absah
JMJoseph A. Murray
Joseph A. Murray

27 June 2025 in Gut
Verified
Journal Article
Closed access
PDF file
JDJohn A Damianos
John A Damianos
ABAdam Bledsoe
Adam Bledsoe
MCMichael Camilleri
Michael Camilleri
JMJoseph A Murray
Joseph A Murray
Coeliac disease is characterised by immune-mediated damage to the small intestine in response to dietary gluten in genetically predisposed individuals. Increased intestinal permeability is a central component to its pathophysiology. This review explores the evidence for increased permeability in coeliac disease and the underlying mechanisms, including the roles of zonulin, inflammatory cytokines, microbial alterations and immune responses to gliadin peptides. We also review comprehensively the therapies targeting barrier integrity and normalising intestinal permeability, including particular diets and supplements, and experimental and improved medications including larazotide acetate and IMU-856. Finally, we highlight the need for reliable biomarkers for evaluating increased permeability in coeliac disease and advocate for further research on therapies which normalise barrier function, particularly as a strategy to maintain remission.

14 July 2026 in Blood Advances
Verified
Journal Article
Open access
KLKenneth J. C. Lim
Kenneth J. C. Lim
HLHee Eun Lee
Hee Eun Lee
ZCZongming Eric Chen
Zongming Eric Chen
ABAdam Bledsoe
Adam Bledsoe
RPRicardo Parrondo
Ricardo Parrondo
LYLi Yin
Li Yin
Immune effector cell–associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.

30 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NWNatalie J. Wu-Woods
Natalie J. Wu-Woods
ARAnna E. Romano
Anna E. Romano
CNChristopher R. Neimeth
Christopher R. Neimeth
AGAnika Gupta
Anika Gupta
XPXinyue (Penny) Pei
Xinyue (Penny) Pei
RIRustem F. Ismagilov
Rustem F. Ismagilov
Genome-resolved virome analysis remains inaccessible for many samples, including those with clinical relevance, because viral nucleic acid recovered after enrichment is often too scarce to support de novo genome assembly. As a result, many analyses are limited to sparse read-level detection, which cannot recover divergent viruses, resolve strains, or interpret gene-level variation. Here, we developed Low Biomass Viral Sequencing (LBV-Seq), a workflow that couples low-input viral sample handling with modified primary template-directed amplification and short- or long-read sequencing to enable de novo reconstruction of DNA and RNA viral genomes from sub-femtogram to nanogram inputs. LBV-Seq reproducibly captures the same relative community composition, amplifies diverse viruses, and achieved broad genome coverage across nearly all targets regardless of viral genome structure, Baltimore class, abundance, or input mass. Short-read assemblies recovered near-complete genomes from femtogram-scale inputs. Long-read sequencing provided orthogonal support for genome structure, with PacBio HiFi reads spanning large portions of viral genomes and, in some cases, complete small viral genomes. Applied to virus-enriched human duodenal biopsy eluates, LBV-Seq provided proof-of-feasibility for recovering both bacteriophage and eukaryotic viral genomes from low-input biopsy-derived material. In the eluates tested, LBV-Seq recovered co-occurring Alphatorquevirus and Betatorquevirus genomes estimated to be present at roughly 10 copies/µL and at viral masses below 0.1 fg/µL. LBV-Seq enables genome-resolved virome analysis in samples previously limited to detection-based viromics, supporting viral discovery and strain-resolved analyses in settings where viral mass is low, including viruses enriched from human tissue biopsies.

1 February 2021 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
GRGuilherme Piovezani Ramos
Guilherme Piovezani Ramos
DBDavid L Bartlett
David L Bartlett
ABAdam Bledsoe
Adam Bledsoe
DBDavid Bruining
David Bruining
JFJeff Fidler
Jeff Fidler
JMJoseph Murray
Joseph Murray